Compare MRAM & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | RZLT |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | 71 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.8M | 321.6M |
| IPO Year | 2016 | 2011 |
| Metric | MRAM | RZLT |
|---|---|---|
| Price | $28.89 | $3.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $18.50 | $9.67 |
| AVG Volume (30 Days) | ★ 5.0M | 1.3M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,417,000.00 | N/A |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $5.49 | $1.07 |
| 52 Week High | $51.50 | $11.46 |
| Indicator | MRAM | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 48.95 |
| Support Level | $8.23 | $2.93 |
| Resistance Level | $51.50 | $3.62 |
| Average True Range (ATR) | 5.51 | 0.21 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 33.54 | 52.78 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.